Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADAR: Atrasentan in Diabetic Nephropathy
NCT01356849Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2011
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of atrasentan in diabetic nephropathy (DN) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Urinary Albumin to Creatinine Ratio at 12 weeks. Started Apr 2011; status: completed.
02
Drugs
atrasentan
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT01356849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01356849.